Matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression is not regulated by norgestimate or norelgestromin

Gynecological Endocrinology

Volumn 18, Issue 1, 2004, Pages 23-27

  Prifti, S ^a,b   Lelle, I ^a   Zhong, G ^c   Strowitzki, T ^a   Rabe, T ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF ATHENS   (Greece)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Elisa; Gelatinase A; MMP 2; Synthetic Progestins; TIMP 2

Indexed keywords

ESTRADIOL; GELATINASE A; GELATINASE B; HYDROXYPROGESTERONE; NORELGESTROMIN; NORGESTIMATE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CANCER CELL; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENDOMETRIUM CANCER; ENDOMETRIUM CELL; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; INCUBATION TIME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERNATANT;

17-ALPHA-HYDROXYPROGESTERONE; CELL LINE, TUMOR; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, SYNTHETIC; ENDOMETRIUM; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; ETHISTERONE; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; NORGESTREL; OXIMES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 1642578258     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590310001651740     Document Type: Article

References (31)

1. Cox G, O'Byrne KJ. Matrix metalloproteinases and cancer. Anticancer Res 2001;21:4207-19
2. Murphy G, Cockett MI, Ward RV, et al. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95kDa and 72kDa gelatinases, stromelysins 1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 1991;277:277-9
3. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases in skin. Exp Dermatol 1997;6:199-213
4. Corcoran ML, Hewitt RE, Kleiner DE, et al. MMP-2: expression, activation and inhibition. Enzyme Protein 1996;49:7-19
5. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002;21:2245-52
6. Bruner KL, Rodgers WH, Gold LI, et al. Transforming growth factor beta mediates the progesterone suppression of an epithelial metalloproteinase by adjacent stroma in the human endometrium. Proc Natl Acad Sci USA 1995; 92:7362-6
7. Marbaix E, Donnez J, Courtoy PJ, et al. Progesterone regulates the activity of collagenase and related gelatinases A and B in human endometrial explants. Proc Natl Acad Sci USA 1992;89:11789-93
8. Hampton AL, Nie G, Salamonsen LA. Progesterone analogues similarly modulate endometrial matrix metalloproteinase-1 and matrix metalloproteinase-3 and their inhibitor in a model for long-term contraceptive effects. Mol Hum Reprod 1999;5:365-71
9. Rodgers WH, Matrisian LM, Giudice LC, et al. Patterns of matrix metalloproteinase expression in cycling endometrium imply differential functions and regulation by steroid hormones. J Clin Invest 1994; 94:946-53
10. Salamonsen LA, Butt AR, Hammond FR, et al. Production of endometrial matrix metalloproteinases, but not their tissue inhibitors, is modulated by progesterone withdrawal in an in vitro model for menstruation. J Clin Endocrinol Metab 1997;82: 1409-15
11. Lockwood CJ, Papp C, Alvarez M, et al. Ovarian steroids regulate stromelysin-1 expression in human endometrial stromal cells. Society for Gynecologic Investigation, 41st Annual Meeting 1994, Abstract O197
12. Holinka CF. Aspects of hormone replacement therapy. Ann NY Acad Sci 1994;734:271-84
13. Mahavni V, Sood AK. Hormone replacement therapy and cancer risk. Curr Opin Oncol 2001;13:384-9
14. Jick SS, Walker AM, Jick H. Oral contraceptives and endometrial cancer. Obstet Gynecol 1993;83:931-5
15. Katsuki Y, Shibutani Y, Aoki D, et al. Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins. Cancer 1997;79:169-76.
16. Kaplan B. Desogestrel, norgestimate, and gestodene: the newer progestins. Ann Pharmacother 1995;29: 736-42
17. Vincent AJ, Salamonsen LA. The role of matrix metalloproteinases and leucocytes in abnormal uterine bleeding associated with progestin-only contraceptives. Hum Reprod 2000;15:135-43
18. Marbaix E, Vekemans M, Galant C, et al. Circulating sex hormones and endometrial stromelysin-1 (matrix metalloproteinase-3) at the start of bleeding episodes in levonorgestrel-implant users. Hum Reprod 2000; 15:120-34
19. Ishiwata I, Ishiwata C, Soma M, et al. Establishment of human endometrial adenocarcinoma cell line containing estradiol-17 beta and progesterone receptors. Gynecol Oncol 1984;17:281-90
20. Park DW, Ryu HS, Choi DS, et al. Localization of matrix metalloproteinases on endometrial cancer cell invasion in vitro. Gynecol Oncol 2001;82:442-9
21. Miyaki E, Yasumitsu H, Hirahara F, et al. Characterization of matrix-degrading proteinases and their inhibitor secreted by human gynecological carcinoma cells. Jpn J Cancer Res 1995;86:568-76
22. Ueda M, Fujii H, Yoshizawa K, et al. Effects of sex steroids and growth factors on migration and invasion of endometrial adenocarcinoma SNG-M cells in vitro. Jpn J Cancer Res 1996;87:524-33
23. Soini Y, Alarakkola E, Autio-Harmainen H. Expression of messenger RNAs for metalloproteinases 2 and 9, type IV collagen, and laminin in non-neoplastic and neoplastic endometrium. Hum Pathol 1997;28:220-6
24. Yabushita H, Narumiya H, Hiratake K, et al. The association of transforming growth factor-beta 1 with myometrial invasion of endometrial carcinomas through effects on matrix metalloproteinase. J Obstet Gynaecol Res 2000;26:163-70
25. Iurlaro M, Loverro G, Vacca A, et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma. Eur J Clin Invest 1999;29:793-801
26. Maatta M, Soini Y, Liakka A, et al. Localization of MT1-MMP, TIMP-1, TIMP-2, and TIMP-3 messenger RNA in normal, hyperplastic, and neoplastic endometrium. Enhanced expression by endometrial adenocarcinomas is associated with low differentiation. Am J Clin Pathol 2000;114:402-11
27. Van den Brule FA, Engel J, Stetler-Stevenson WG, et al. Genes involved in tumor invasion and metastasis are differentially modulated by estradiol and progestin in human breast cancer cells. Int J Cancer 1992; 52:653-7
28. Zhang J, Hampton AL, Nie G, et al. Progesterone inhibits activation of latent matrix metalloproteinase (MMP)-2 by membrane-type 1 MMP: enzymes coordinately expressed in human endometrium. Biol Reprod 2000;62:85-94
29. Irvin JC, Kirk D, Gwatkin RB, et al. Human endometrial matrix metalloproteinase-2, a putative menstruation proteinase. Hormonal regulation in cultured stromal cells and messenger RNA expression during the menstrual cycle. J Clin Invest 1996; 97:273-4
30. Lockwood CJ, Krikun G, Hausknecht VA, et al. Matrix metalloproteinase and matrix metalloproteinase inhibitor expression in endometrial stromal cells during progestin-initiated decidualization and menstruation-related progestin withdrawal. Endocrinology 1998;139:4607-13
31. Hickey M, Higham J, Sullivan M, et al. Endometrial bleeding in hormone replacement therapy users: preliminary findings regarding the role of matrix metalloproteinase 9 (MMP-9) and tissue inhibitors of MMPs. Fertil Steril 2001;75:288-96